DioGenix, Inc. is a privately-held molecular diagnostics company developing and commercializing novel tests to aid in difficult healthcare decisions associated with multiple sclerosis (MS) and other neurological diseases.

Our lead product is MSPrecise®, a first-in-class next-generation sequencing assay to identify patients with MS at first clinical presentation. This product is now being validated in the largest prospective diagnostic clinical trial of its kind and is a natural evolution of the current standard of care. By profiling molecular changes resulting from established immune adaptations, MSPrecise® has shown across multiple clinical studies to be more specific and sensitive in determining the presence of disease. MSPrecise® will be followed by other DioGenix offerings that use a similar approach in other immune-mediated diseases of the central nervous system and which may benefit from analysis of more easily accessible biofluids.